SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

April 29, 2011 07:00 ET

SciClone Pharmaceuticals to Report First Quarter 2011 Results on May 10

FOSTER CITY, CA--(Marketwire - Apr 29, 2011) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2011 results on Tuesday, May 10, 2011. SciClone is hosting a conference call at 8:30 am ET to provide a financial update. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, Gary Titus, Senior Vice President and CFO, and Mark Lotter, CEO of China Operations.

LIVE CALL:866.831.6224 (U.S./Canada)
617.213.8853 (International)
Passcode: 17214706
REPLAY:888-286-8010 (U.S./Canada)
617-801-6888 (International)
Passcode: 48552379

(Replay available from Tuesday, May 10, 2011, at 11:30am ET until 11:59 pm ET on Tuesday, May 17, 2011)

The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is only accurate at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.

About SciClone
SciClone Pharmaceuticals is a revenue-generating, China-centric specialty pharmaceutical company with a substantial business and a product portfolio of novel therapies for cancer, infectious diseases and cardiovascular, urology and central nervous system disorders, and respiratory conditions. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries for the treatment of hepatitis B (HBV), as a vaccine adjuvant, for the treatment of hepatitis C (HCV), and certain cancers. SciClone markets nearly 20 products in China besides ZADAXIN, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, Tritace, an ACE inhibitor for the treatment of hypertension, Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US), and Aggrastat®, a recently-launched intervention cardiology product. On the development side, SciClone is evaluating SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.

Ambien, Depakine and Stilnox are registered trademarks of Sanofi-Aventis.

Aggrastat is a registered trademark of Merck & Co., Inc.

Contact Information